Keiichi Fujiwara

25PUBLICATIONS
163CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Aerospace materialsPredictive and prognostic markersPacific Peoples nursingMedical ethics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jul 13, 2026
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.

|Sep 19, 2025
Erratum: The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization.

David Tan, Noriko Fujiwara, Keiichi Fujiwara

|Jul 02, 2025
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.

Yann Christinat, Intidhar Labidi-Galy, Liza Ho

|Jan 28, 2025
Intraperitoneal chemotherapy is now back for ovarian cancer.

Keiichi Fujiwara, Shoji Nagao, David Tan

|Jun 23, 2024
The International Gynecologic Cancer Society consensus statement on palliative care.

Keiichi Fujiwara, Stephen R Connor, Noriko Fujiwara

|Feb 01, 2024
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.

Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa

Pageof 5

Frequent Collaborators

5 joint publications

Kosei Hasegawa

5 joint publications

Noriko Fujiwara

4 joint publications

Byoung-Gie Kim

4 joint publications

Jae-Weon Kim